Neurenati Therapeutics concluded a $1.2M seed financing round led by Genson Capital to develop NEU-001 as a promising therapy for Hirschsprung Disease.
Amount Raised
$1.2 Million
Round Type
Seed
MontrealBiotechnologyHealth CareTherapeuticsInvestors
Description
Neurenati Therapeutics has successfully closed a seed funding round, securing $1.2 million from Genson Capital on the 2024 Rare Disease Day. The funding will accelerate the development of NEU-001, a first-in-class therapy for Hirschsprung’s disease (HSCR), a rare gastrointestinal condition. The company aims to file an Investigational New Drug (IND) application for NEU-001 in the second half of 2025. The seed round will remain open for additional funding in 2024.
Quick answer
Neurenati Therapeutics raised $1.2 Million in a Seed round, dated February 29, 2024. Investors: Cqdm Synergi Qc and Genson Capital. Neurenati Therapeutics is based in Montreal, Quebec, Canada.
- How much did Neurenati Therapeutics raise?
- Neurenati Therapeutics raised $1.2 Million in a Seed round on February 29, 2024.
- Who invested in Neurenati Therapeutics?
- Cqdm Synergi Qc and Genson Capital are named as investors in this round.
- What does Neurenati Therapeutics do?
- Neurenati Therapeutics is a Québec-based biotech company dedicated to developing therapies for rare diseases.
- Where is Neurenati Therapeutics based and how big is it?
- Neurenati Therapeutics is based in Montreal, Quebec, Canada.
- Who are the decision-makers at Neurenati Therapeutics?
- Fundz holds 1 contact at Neurenati Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Neurenati Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- FundaMental Pharma raised $14M (Seed) on April 11, 2024.
- TORL BioTherapeutics raised $158M (Series B) on April 10, 2024.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- D3 Bio raised $62M (Series A) on April 8, 2024.
- Beacon Therapeutics raised $120M (Series A) on April 5, 2024.
- TORL BioTherapeutics raised $158M on April 4, 2024.
Who to call at Neurenati Therapeutics, and when
A new round usually means Neurenati Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Neurenati Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neurenati Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neurenati Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Neurenati Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Neurenati Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.